2004
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Herbst R, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, Mass R, Johnson D. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7011-7011. DOI: 10.1200/jco.2004.22.14_suppl.7011.Peer-Reviewed Original ResearchLong survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE
Miller V, Herbst R, Prager D, Fehrenbacher L, Hermann R, Hoffman P, Johnson B, Sandler A, Kris M, Ramies D. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Journal Of Clinical Oncology 2004, 22: 7061-7061. DOI: 10.1200/jco.2004.22.14_suppl.7061.Peer-Reviewed Original ResearchTRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Herbst R, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, Mass R, Johnson D. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7011-7011. DOI: 10.1200/jco.2004.22.90140.7011.Peer-Reviewed Original ResearchLong survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE
Miller V, Herbst R, Prager D, Fehrenbacher L, Hermann R, Hoffman P, Johnson B, Sandler A, Kris M, Ramies D. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Journal Of Clinical Oncology 2004, 22: 7061-7061. DOI: 10.1200/jco.2004.22.90140.7061.Peer-Reviewed Original Research
2003
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer
Herbst R, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. 977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. European Journal Of Cancer Supplements 2003, 1: s293. DOI: 10.1016/s1359-6349(03)91004-4.Peer-Reviewed Original Research